2/17/04

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Wilson
				Group Art Unit	Not Yet Assigned
(use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	5623-13

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	5,719,279		Kufner-Muhl et al.	02-17-1998
	2	5,786,360		Constance Neely	07-28-1998
	3	2002/0058667		Castelhano et al.	05-16-2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Foreign Patent Document Number	Foreign Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	4	BELARDINELLI ET AL., *1, 3-Dipropyl-8-[2-(5, 6-Epoxy)Norbomyl]Xanthine, a Potent Specific and Selective A_1 Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT $_1$MF-2 Cells*, The Journal of Pharmacology and Experimental Therapeutics, Vol. **276**, No. 2:1167-1176 (1995)	
	5	BEAUGLEHOLE ET AL., *New Irreversible Adenosine A_1 Antagonists Based on FSCPX*, Bioorganic and Medicinal Chemistry Letters, **12**:3179-3182 (2002)	
	6	BEAUGLEHOLE ET AL., *Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A_1-Adenosine Receptor*, J. Med. Chem. **43**:4973-4980 (2000)	
	7	SONJA HESS, *Recent Advances in Adenosine Receptor Antagonist Research*, Expert Opinion, Ashley Publications, 1354-3776 (2001)	
	8	JACOBSON ET AL., *Adenosine Receptors: Pharmacology, Structure-Activity Relationships; and Therapeutic Potential*, Journal of Medicinal Chemistry, Vol. **35**, No. 3:407-422 (February 7, 1992)	
	9	KURODA ET AL., *Design, Synthesis and Biological Evaluation of a Novel Series of Potent, Orally Active Adenosine A_1 Receptor Antagonists with High Blood-Brain Barrier Permeability*, Chem. Pharm. Bull., **49**:988-998 (2001)	
	10	NICOT ET AL., *High-Performance Liquid Chromatographic Method for the Determination of Bamifylline and it's Three Metabolites in Human Plasma*, Journal of Chromatography, **277**:239-249 (1983)	
	11	NOVELLINO ET AL., *Design, Synthesis and Biological Evaluation of Novel N-Alkyl-and N-Acyl-(7-subsituted-2-2phenylimidazo[1.2-a] [1,3,5] triaxzin-4-yl] amines (ITAs) as Novel A_1 Adenosine Receptor Antagonists*, J. Med. Chem. **45**:5030-5036 (2002)	
	12	SACCHI ET AL., *Research on Heterocyclic Compounds. Part XXXVI. Imidazo[1,2-a]pyrimidine-2-acetic derivatives: synthesis and anti-inflammatory activity*, Eur. J. Med. Chem., **32**:677-682 (1997)	
	13	SCAMMELLS ET AL., *Substituted 1,3-Dipropylxanthines as Irreversible Antagonists of A_1 Adenosine Receptors*, J. Med. Chem. **37**:2704-2712 (1994)	
	14	VAN MUIJLWIJK-KOEZEN ET AL., *Synthesis and Use of FSCPX, an Irreversible Adenosine A_1 Antagonist, as a 'Receptor Knock-Down' Tool*, Bioorganic & Medicinal Chemistry Letters, **11**:815-818 (2001)	
	15	VAN GALEN ET AL., *A Model for the Antagonist Binding Site on the Adenosine A_1 Receptor, Based on Steric, Electrostatic, and Hydrophobic Properties*, J. Med. Chem., **33**:1708-1713 (1990)	
	16	VAN TILBURG ET AL., *Subsituted 4-Phenyl-2-2(phenylcarboxamido)-1,3-thiazole Derivatives as Antagonists for the Adenosine A_1 Receptor*, Bioorganic & Medicinal Chemistry Letters, **11**:2017-2019 (2001)	
	17	WILSON ET AL., *Lipopolysaccaride Binds to and Activates A_1 Adenosine Receptors on Human Pulmonary Artery Endothelial Cells*, Journal of Endotoxin Research, Vol. **8**, No. 4:263-271 (2002)	
		POULSEN, BIOORGANIC & MEDICINAL CHEM. LET. 6,619 (1998)	

Examiner Signature		Date Considered	1/31/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO
(Revised 04/2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1

Complete if Known	
Application Number	10/780,296
Filing Date	2/17/04
First Named Inventor	Wilson
Group Art Unit	1614
Examiner Name	To be Assigned
Attorney Docket Number	049542/283879

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MP	1	US-2004/0014766 A1	01-22-2004	DUNTEN *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
MP	2	FOLEY, L.H. *et al.*, "Modified 3-Alkyl-1, 8-dibenzylxanthines as GTP-Competitive Inhibitors of Phosphoenolpyruvate Carboxykinase," *Bioorganic & Medicinal Chemistry Letters*," 2003, pp. 3607-3610, Vol. 13.	

Examiner Signature		Date Considered	1/31/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.